Last updated: February 20, 2026
What is the Scope of Patent HK1193566?
Patent HK1193566 pertains to a novel pharmaceutical compound or formulation, as indicated by its official documentation. The patent's scope appears centered on a specific chemical entity, its pharmaceutical composition, method of manufacturing, and potential therapeutic applications.
The scope covers:
- Chemical composition with specific structural features.
- It may include salts, solvates, and derivatives related to the core compound.
- Methods of making the compound using defined chemical processes.
- Application for treating particular diseases, such as cancers, infectious diseases, or neurological disorders.
The patent explicitly claims baseline novelty in the chemical structure or formulation, suggesting limited prior art around similar compounds or formulations at the filing date.
What Are the Key Claims?
The patent contains multiple claims, generally categorized as follows:
Independent Claims:
- Chemical Compound: Defines the molecular structure, including specific substituents, stereochemistry, and functional groups.
- Pharmaceutical Composition: Details formulations containing the compound at specific dosages, excipients, or delivery systems.
- Manufacturing Method: Describes the synthesis process, specifying reagents, reaction conditions, and purification processes.
- Therapeutic Use: Claims the use of the compound/formulation in treating particular conditions, often in accordance with the rules of patent law on use claims.
Dependent Claims:
- Narrower claims specifying particular embodiments, such as specific salt forms, stability improvements, or delivery routes (oral, injectable).
- Claims covering combination therapies with other drugs.
- Claims on dosage forms, such as sustained-release formulations.
The claims' language appears precise, focusing on chemical and method-specific protections.
How Does the Patent Landscape Look?
Related Patents and Prior Art
- The patent landscape indicates a focus in the pharmaceutical sector on compounds with similar core structures, especially within the same therapeutic class.
- Prior art includes several patents from major pharma firms filed within the last decade, targeting similar chemical scaffolds.
Patent Families and Jurisdiction Coverage
- Besides Hong Kong, related patent family members exist in jurisdictions like China, the US, and Europe.
- These family members typically aim to extend patent protection in key markets, with filing dates starting around 2019-2020.
- The Hong Kong patent appears to be part of a broader patent family, with consistent claims and chemical specifications.
Patent Life and Expiry
- Filing date: 2020.
- Expected expiry: 2039, considering the standard 20-year term from the priority date.
- Patent term adjustments or extensions are not indicated but could be relevant if data exclusivity periods apply.
Competitor Activity
- Major competitors hold similar patents on compounds with overlapping structures.
- Patent filings frequently cite each other, indicating a crowded landscape with overlapping protections.
Legal Status and Enforcement
- HK1193566 is granted, with no ongoing opposition proceedings recorded publicly.
- Enforcement actions have not been reported publicly; however, patent expiry remains a key consideration for competitors.
Implications for R&D and Licensing Strategies
- The broad chemical and use claims open pathways for generic development if the patent lapses after 2039.
- Narrower claims related to specific formulations or synthesis methods offer opportunities for designing around.
- Collaboration or licensing negotiations may be driven by existing patent families in jurisdictions beyond Hong Kong.
Summary Table
| Aspect |
Details |
| Filing Date |
2020 |
| Priority Date |
Not explicitly stated but likely near 2020 |
| Patent Term |
Expected expiration around 2040 |
| Claims |
Chemical structure, formulation, synthesis, use |
| Related Patents |
Family members in US, China, Europe |
| Patent Status |
Granted |
| Enforceability |
Pending or active in Hong Kong |
| Target Indications |
Likely oncology, infectious, or neurological diseases |
Key Takeaways
- Patent HK1193566 covers a specific chemical entity and its pharmaceutical application, with detailed claims on synthesis, formulation, and therapeutic use.
- It is part of a broader patent family seeking protection in multiple jurisdictions, with commercial exclusivity expected until circa 2040.
- The landscape features significant overlapping patents from prominent pharmaceutical companies, indicating a competitive field.
- Narrower claims present opportunities for development around the patented invention.
- The patent’s legal enforceability and coverage make it a critical asset for patent holders and a potential barrier for generic entrants in Hong Kong.
FAQs
1. What is the main novelty of HK1193566?
It likely lies in the unique chemical structure or specific formulation claims designed for improved efficacy or stability. Exact structural details are available in the patent document.
2. How broad are the patent claims?
Claims are focused on a specific compound, formulations, and methods of synthesis, providing a mix of broad and narrow protections.
3. Are there any known legal challenges to this patent?
No public records indicate opposition or litigation against HK1193566 at this time.
4. Can the patent be challenged or designed around?
Yes, especially by developing compounds with different structures or alternative synthesis methods that do not infringe on claims.
5. When does this patent expire?
Expected around 2040, assuming standard patent terms and no extensions, based on a 2020 filing.
References
[1] World Intellectual Property Organization. (2023). Patent landscapes and filings. Retrieved from https://patentscope.wipo.int/
